Jump to content

CR-4056

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 15:12, 21 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

CR-4056
Identifiers
  • 6-(1H-imidazol-1-yl)-2-phenylquinazoline
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC17H12N4
Molar mass272.311 g·mol−1
3D model (JSmol)
  • C1(C2=CC=CC=C2)=NC=C3C=C(N4C=CN=C4)C=CC3=N1
  • InChI=1S/C17H12N4/c1-2-4-13(5-3-1)17-19-11-14-10-15(6-7-16(14)20-17)21-9-8-18-12-21/h1-12H
  • Key:CSZGXYBGYFNSCO-UHFFFAOYSA-N

CR-4056 is an analgesic drug candidate with a novel mechanism of action, acting as a ligand for the imidazoline receptor I2. It showed promising results in animal studies against various types of neuropathic pain, and has reached Phase II human clinical trials as a potential treatment for pain associated with osteoarthritis.[1][2][3][4][5]

References

  1. ^ Ferrari F, Fiorentino S, Mennuni L, Garofalo P, Letari O, Mandelli S, Giordani A, Lanza M, Caselli G (2011). "Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain". Journal of Pain Research. 4: 111–25. doi:10.2147/JPR.S18353. PMC 3100226. PMID 21647215.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  2. ^ Li JX, Thorn DA, Qiu Y, Peng BW, Zhang Y (March 2014). "Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain". British Journal of Pharmacology. 171 (6): 1580–90. doi:10.1111/bph.12555. PMC 3954494. PMID 24329196.
  3. ^ Comi E, Lanza M, Ferrari F, Mauri V, Caselli G, Rovati LC (May 4, 2017). "Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis". Journal of Pain Research. 10: 1033–1043. doi:10.2147/JPR.S132026. PMC 5422496. PMID 28496359.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  4. ^ Li JX (October 2017). "2 receptors: An update". Pharmacology & Therapeutics. 178: 48–56. doi:10.1016/j.pharmthera.2017.03.009. PMC 5600648. PMID 28322973.
  5. ^ Rovati LC, Brambilla N, Blicharski T, Probert NJ, Vitalini C, Giacovelli G, Girolami F, D'Amato M (2017). "A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial of the First-in-Class Imidazoline-2 Receptor Ligand CR4056 in Pain from Knee Osteoarthritis and Disease Phenotypes". Arthritis Rheumatol. 69 (suppl 10). 2017 ACR/ARHP Annual Meeting, Abstract 1193.{{cite journal}}: CS1 maint: location (link)
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=CR-4056&oldid=963743385"